Department of Pharmaceutical Sciences, 262 Danny Thomas Place, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
J Pharmacol Exp Ther. 2010 Mar;332(3):1088-99. doi: 10.1124/jpet.109.160804. Epub 2009 Nov 24.
Variability in hepatic CYP3A4 cannot be explained by common CYP3A4 coding variants. We previously identified polymorphisms in pregnane X receptor (PXR) and ATP-binding cassette subfamily B member 1 (ABCB1) associated with CYP3A4 mRNA levels in small cohorts of human livers. However, the relative contributions of these genetic variations or of polymorphisms in other CYP3A4 regulators to variable CYP3A4 expression were not known. We phenotyped livers from white donors (n = 128) by quantitative real-time polymerase chain reaction for expression of CYP3A4, CYP3A5, and CYP3A7 and nine transcriptional regulators, coactivators, and corepressors. We resequenced hepatic nuclear factor-3-beta (HNF3beta, FoxA2), HNF4alpha, HNF3gamma (FoxA3), nuclear receptor corepressor 2 (NCoR2), and regions of the CYP3A4 promoter and genotyped informative single-nucleotide polymorphisms in PXR and ABCB1 in the same livers. CYP3A4 mRNA was positively correlated with PXR and FoxA2 and negatively correlated with NCoR2 mRNA. A common silent polymorphism and a polymorphic trinucleotide (CCT) repeat in FoxA2 were associated with CYP3A4 expression. The transcriptional activity of the FoxA2 polymorphic CCT repeat alleles (wild-type, n = 14 and variant, n = 13, 15, and 19) when assayed by luciferase reporter transactivation assays was greatest for the wild-type repeat, with deviations from this number having decreased transcriptional activity. This corresponded with higher expression of FoxA2 mRNA and its targets PXR and CYP3A4 in human livers with (CCT) n = 14 genotypes. Multiple linear regression analysis was used to quantify the contributions of selected genetic polymorphisms to variable CYP3A4 expression. This approach identified sex and polymorphisms in FoxA2, HNF4alpha, FoxA3, PXR, ABCB1, and the CYP3A4 promoter that together explained as much as 24.6% of the variation in hepatic CYP3A4 expression.
肝 CYP3A4 的变异性不能用常见的 CYP3A4 编码变异来解释。我们之前在小样本人类肝脏中发现了与 CYP3A4 mRNA 水平相关的 pregnane X 受体 (PXR) 和 ATP 结合盒亚家族 B 成员 1 (ABCB1) 的多态性。然而,这些遗传变异或其他 CYP3A4 调节剂的多态性对 CYP3A4 表达的可变表达的相对贡献尚不清楚。我们通过定量实时聚合酶链反应对来自白人供体 (n = 128) 的肝脏表型进行了 CYP3A4、CYP3A5 和 CYP3A7 以及九个转录调节剂、共激活因子和核心抑制剂的表达分析。我们对核因子-3-β (HNF3β,FoxA2)、HNF4α、HNF3γ (FoxA3)、核受体共抑制因子 2 (NCoR2) 和 CYP3A4 启动子区域进行了重测序,并在相同的肝脏中对 PXR 和 ABCB1 中的信息单核苷酸多态性进行了基因分型。CYP3A4 mRNA 与 PXR 和 FoxA2 呈正相关,与 NCoR2 mRNA 呈负相关。FoxA2 中的一个常见沉默多态性和一个多态三核苷酸 (CCT) 重复与 CYP3A4 表达有关。当通过荧光素酶报告基因转染实验检测 FoxA2 多态性 CCT 重复等位基因 (野生型,n = 14 和变异型,n = 13、15 和 19) 的转录活性时,野生型重复的活性最大,偏离此数的活性降低。这与人类肝脏中 FoxA2 mRNA 及其靶基因 PXR 和 CYP3A4 的表达较高相对应,这些基因的(CCT)n = 14 基因型。多元线性回归分析用于量化选定遗传多态性对 CYP3A4 表达的可变贡献。这种方法确定了性别和 FoxA2、HNF4α、FoxA3、PXR、ABCB1 和 CYP3A4 启动子中的多态性,它们共同解释了肝 CYP3A4 表达变异性的 24.6%。
J Pharmacol Exp Ther. 2009-11-24
Clin Pharmacol Ther. 2006-4
Basic Clin Pharmacol Toxicol. 2015-10
Adv Drug Deliv Rev. 2002-11-18
Pharmaceuticals (Basel). 2024-4-8
Front Pharmacol. 2022-6-16
Front Pharmacol. 2020-10-2
J Clin Invest. 2009-6
Physiol Genomics. 2009-7-9
Drug Metab Pharmacokinet. 2008
Pharmacogenomics. 2007-5